{"id":"enpatoran-low-dose","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"null","effect":"Genital amputation"},{"rate":"null","effect":"Increased risk of acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL4802159","moleculeType":"Small molecule","molecularWeight":"320.32"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, Enpatoran low dose reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is associated with various therapeutic benefits, including improved glycemic control and potential cardiovascular protection.","oneSentence":"Enpatoran low dose is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:50:55.393Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic kidney disease (CKD) with or without diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT05540327","phase":"PHASE2","title":"The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-09-16","conditions":"Systemic Lupus Erythematosus","enrollment":379},{"nctId":"NCT05162586","phase":"PHASE2","title":"The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-03-31","conditions":"Systemic Lupus Erythematosus","enrollment":456},{"nctId":"NCT06589726","phase":"PHASE1","title":"A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-09-10","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["M5049"],"phase":"phase_2","status":"active","brandName":"Enpatoran low dose","genericName":"Enpatoran low dose","companyName":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","companyId":"merck-healthcare-kgaa-darmstadt-germany-an-affiliate-of-merck-kgaa-darmstadt-ger","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enpatoran low dose is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Chronic kidney disease (CKD) with or without diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}